Development of quantitative mass spectrometric immunoassay for serum amyloid A

Olgica Trenchevska; Hussein N Yassine; Chad R Borges; Randall W Nelson; Dobrin Nedelkov

doi:10.1080/1354750X.2016.1201533

Development of quantitative mass spectrometric immunoassay for serum amyloid A

Biomarkers. 2016 Dec;21(8):743-751. doi: 10.1080/1354750X.2016.1201533. Epub 2016 Jul 22.

Authors

Olgica Trenchevska¹, Hussein N Yassine², Chad R Borges¹, Randall W Nelson¹, Dobrin Nedelkov¹

Affiliations

¹ a The Biodesign Institute, Arizona State University , Tempe , AZ , USA.
² b Department of Medicine , University of Southern California , Los Angeles , CA , USA.

Abstract

Objective: Proteins can exist as multiple proteoforms in vivo that can have important roles in physiological and pathological states.

Methods: We present the development and characterization of mass spectrometric immunoassay (MSIA) for quantitative determination of serum amyloid A (SAA) proteoforms.

Results: Intra- and inter-day precision revealed CVs <10%. Against existing SAA ELISA, the developed MSIA showed good correlation according to the Altman-Bland plot. Individual concentrations of the SAA proteoforms across a cohort of 170 samples revealed 7 diverse SAA polymorphic types and 12 different proteoforms.

Conclusion: The new SAA MSIA enables parallel analysis of SAA polymorphisms and quantification of all expressed SAA proteoforms, in a high-throughput and time-efficient manner.

Keywords: Baseline concentration; inflammation biomarker; mass spectrometry; polymorphism; posttranslational modifications; proteoforms.

Abstract

Grants and funding